At USTC’s Suzhou institute of Nano-Tech and Nano-Bionics, I designed an on-chip screening strategy to identify TCR-mimic antibody candidates and used these antibodies to develop or optimize immunotherapies, including bispecific antibodies and CAR-T. My work on a bispecific NK-cell engager targeting a TP53 mutation was published in MedComm.
At Soochow University, I worked on cell-penetrating peptides for cancer immunotherapy and personalized nanovaccines based on fluoropolymers. At WuXi AppTec, I optimized in-vitro protocols for Th2 and Treg cell differentiation and NK-cell activation.
